Kornimate/medical-research-clean huggingface dataset:
high-flow nasal cannula oxygenation decrease hypoxia in gastroscopy sedated by propofol

Conditions: Hypoxia; Gastric Cancer; Esophagus Cancer; Adverse Event

Summary: hypoxia is the most common adverse events during sedated gastroscopy. in present study, high-flow nasal cannula oxygenation will be utilized in order to reduce the hypoxia. at the same time the feasibility and safety will be evaluated.


Eligibility criteria:
inclusion criteria: * patients undergoing gastroscope * age over 18 years old * signed informed consent form exclusion criteria: * coagulation disorders or a tendency of nose bleeding; * an episode/exacerbation of congestive heart failure (chf) that requires a change in medication, diet or hospitalization from any cause in the last 6 months; * severe aortic stenosis or mitral stenosis; * cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (cabg), valve replacement surgery) in the last 6 months; * acute myocardial infarction in the last 6 months; * acute arrhythmia (including any tachycardia - or bradycardia) with hemodynamic instability; * diagnosed chronic obstructive pulmonary disease or current other acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy); * increased intracranial pressure; * asa \>iii; * mouth, nose, or throat infection; * fever, defined as core body temperature \> 37.5oc ; * pregnancy, breastfeeding or positive pregnancy test * emergency procedure

Keywords: hypoxia gastroscope high-flow nasal cannula
intervention with omega fatty acids in high-risk patients

Conditions: Cardiovascular Disease

Summary: in order to reduce cardiovascular risk, current european guidelines recommend a diet low on saturated fatty acid through replacement with polyunsaturated fatty acids (pufa). polyunsaturated fatty acids can be classified into omega-3 and omega-6. however the results from recent meta-analyses investigating coronary risk outcomes did not clearly support a low intake of saturated fatty acids and a high intake of omega-3 or omega-6. the aim of this study is to investigate the short term effects of a high intake of pufas on microvascular function, lipids, inflammation and other cardiovascular risk factors in inactive patients with increased waistline.


Eligibility criteria:
inclusion criteria: * waist circumference ≥ 94 cm in men and ≥ 80 cm in women * physical inactivity (\< 2 h vigorous/active exercise training per week) exclusion criteria: * regular use of certain prescription medications at baseline * severe psychiatric illness * pregnancy * pacemaker or implantable cardioverter defibrillator * cigarette smoking * previous coronary intervention * concomitant use of dietary supplements * use of omega-3 supplements at baseline * alcohol or drug abuse or any condition associated with poor compliance. * scheduled hospitalisation during the course of the study. * participation in a clinical trial in the last 12 weeks, or prior randomisation. * blood donation within the preceding 12 weeks. * diabetes mellitus type 1 or type 2 * triglycerides \> 5 mmol/l * previous bariatric surgery * malabsorption disorder
maximal repair versus bridging reconstruction with biobrace®

Conditions: Rotator Cuff Tears; Bioinductive Implant

Summary: the purpose of this study is to determine if using biobrace® to reconstruct the gap in the rotator cuff tears lead to better results for patients compared to the traditional maximal repair method. this study will use a variety of clinical, radiographic, and functional outcome measures. specifically, the researchers will be comparing the re-tear rate, patient reported outcomes, shoulder strength, range of motion, muscle activation, in-vivo biomechanics, and other radiographic outcomes using x-ray and mri.


Eligibility criteria:
inclusion criteria: * magnetic resonance imaging (mri) proven diagnosis of a large or massive (\> 3cm), two-tendon (supraspinatus and infraspinatus) tear of the shoulder rotator cuff * over 18 years of age exclusion criteria: * glenohumeral osteoarthritis * western ontario rotator cuff score \>60 * uncontrolled diabetes (hgb a1c \>7%) * pregnant * local or systemic infection * inability to cooperate with and/or comprehend post-operative instructions * mri proven non-vascular sites * poor nutritional state (alb \<30 g/l) * cancer * paralysis of the shoulder * contracture of the shoulder * patients unable to provide informed consent for the study

Keywords: shoulder rotator cuff clinical outcomes radiographic outcomes biomechanics bridging reconstruction rotator cuff repair
surveillance of ocular surface flora (surface)

Conditions: Cataract

Summary: topical fluoroquinolones (fqs) have achieved widespread use in ophthalmology for both the treatment and prophylaxis of ocular infections. the present study is set to determine the bacteria present on the ocular surface in patients at the time of cataract surgery and to assess the rate of resistance of ocular isolates to commonly used topical antibiotics.


Eligibility criteria:
inclusion criteria: * scheduled to undergo cataract surgery * able to provide written informed consent exclusion criteria: * nsaid in the eye to be swabbed within the past 30 days * topical anesthetic, topical antibiotic or antiseptic, or dilating drops in the eye to the swabbed within the past 7 days * over-the-counter artificial tear drops or astringent /redness reliever drops (e.g., visine®, clear eyes® in the eye to be swabbed on the day of trial * history of conjunctivitis or any ocular infection within the past 3 months
cerament g device registry

Conditions: Chronic Osteomyelitis; Fracture Related Infection; Diabetic Foot Osteomyelitis

Summary: this is an observational device registry study of cerament\|g in normal use in accordance with the ifu. it will run for a period of three years from enrolment of the first patient into the study at each site, before being subject to review. a device registry is a form of observational study that concerns the performance of a device in normal use. it is intended to collect data that is reflective of 'real world' device performance.


Eligibility criteria:
inclusion criteria: * 18 years and over (on the day of surgery) * receive cerament\|g as a component of their treatment at a participating, contracted centre or healthcare provider, in accordance with the ifu for the implanted product * in receipt of patient information leaflet and have signed appropriately designed informed consent form. exclusion criteria: * any exclusion criteria as per ifu for cerament\|g * any off-label use
molecular characteristics of the persistent intestinal fistulae after glue application

Conditions: Enterocutaneous Fistulas

Summary: for non-healing ulcers, abnormal periods of wound healing processes: inflammation, proliferation and remodelling, are believed to lead to chronic wounds. as a chronic "stalled" wound, investigators hypothesized that these glue-assisted closure (gac)-failed enterocutaneous fistula (ecf) might have a prolonged inflammatory phase modulated by excessive pro-inflammatory cytokines or proteases. the aim of this study was to analyze the chemicals in ecf wounds in order to determine patients' condition and fitness for gac.


Eligibility criteria:
inclusion criteria: * above 18 years old; * single tubular (tract length \>2 cm) ecf; * low output volume (\<200 ml/24h); exclusion criteria: * fistulas of cancer-infiltrated; * associated abscess; * foreign bodies; * distal bowel obstruction;
comparison of pulmonary telerehabilitation and physical activity recommendations in patients with post covid fibrosis

Conditions: COVID-19; Pulmonary Fibrosis

Summary: rehabilitation plays a very important role in the management of patients with covid-19, focusing on respiratory and motor functions, and therefore the importance of establishing treatment strategies to ensure optimal recovery of these patients has been emphasized. it has been stated that physical activity recommendations should be clarified for the management of symptoms associated with prolonged covid-19 syndrome and for the continuation of activities of daily living. it has been stated that after covid-19 pneumonia, it is necessary to evaluate the physical functions of patients with long-term follow-up and to establish rehabilitation programs. the importance of being included in the rehabilitation program was emphasized, especially for patients with lung fibrosis. the primary aim of this study was to compare the effects of pulmonary telerehabilitation and physical activity recommendations on exercise capacity and peripheral muscle strength in patients with pulmonary fibrosis due to covid-19. the secondary aim of this study is to compare the effects of pulmonary telerehabilitation and physical activity recommendations on symptoms, activity and participation in patients with pulmonary fibrosis due to covid-19.


Eligibility criteria:
inclusion criteria: * \>18 years old * patients who have been infected with the covid-19 virus at least three months ago and have been diagnosed with a positive pcr * patients with post-covid-19 pulmonary fibrosis followed by a pulmonologist * patients who have sufficient technological infrastructure to participate in the telerehabilitation program and can adapt to online systems * patients who are clinically stable exclusion criteria: * patients with orthopedic/neurological problems that prevent walking and exercise * patients with uncontrolled cardiovascular disease * patients with uncontrolled medical conditions

Keywords: post covid fibrosis pulmonary rehabilitation physical activity
thulium fiber laser prospective trial

Conditions: Kidney Stone

Summary: this is a multi-center, prospective clinical trial to assess the effect of tfl for the lithotripsy of kidney stones.

flexible ureteroscopy is considered the first-line therapy for renal stones \< 2 cm. the holmium: yag laser (ho:yag) is established as gold standard in urology practice. despite its limitations, it is widely used to break stones into fragments small enough to remove or pass spontaneously through the ureter. advances in the understanding of laser energy delivery have led to the recent commercialization of the 'thulium fiber laser' (tfl) with unique characteristics and promising improvements of ablation efficiency, dusting capacity, operating time and deflection. a a multi-center, prospective clinical trial to further assess those advantages for the lithotripsy of kidney stones will be conducted.

Eligibility criteria:
inclusion criteria: * solitary renal stone 8 to 20 mm in size or in the case of multiple stones the conglomerate diameter of 8-20 mm is required * must be a suitable operative candidate for flexible ureteroscopy per urologic guidelines * must be 18 years or older * must be able to give consent * bilateral ureteroscopy will be permitted but only the first side will be included in the study exclusion criteria: * concomitant stones in the ureter * prior ipsilateral upper urinary tract reconstructive procedures or history of ipsilateral ureteral stricture * prior radiotherapy to the abdomen or pelvis * neurogenic bladder or spinal cord injury * pregnancy * untreated urinary tract infection (uti)

Keywords: ureteroscopy lithotripsy thulium fiber laser
a study of the efficacy and safety of mt1621 in thymidine kinase 2 (tk2) deficiency (treatment naïve)

Conditions: Thymidine Kinase 2 Deficiency

Summary: this is a phase 3b, prospective, single-arm, multicenter, open-label treatment study of the efficacy and safety of mt1621 in pediatric and adolescent patients with thymidine kinase 2 deficiency (tk2d). in order to be eligible for this study, participants must have genetic confirmation of tk2d and must not have ever received mt1621 or nucleos(t)ides before entering the study.

thymidine kinase 2 (tk2) is a protein involved in the normal function of mitochondria. thymidine kinase 2 deficiency (tk2d) is a form of mitochondrial dna depletion syndrome and is a very rare inherited genetic disorder. tk2d leads to abnormally low amounts of dna in mitochondria and because of this defect, the mitochondria are not able to provide the energy that cells need to function properly, which causes severe muscle weakness, along with host of additional symptoms that may involve the respiration, feeding, and ambulation, and can progress until patients lose many of these abilities. there are no fda-approved medicines to treat tk2d. mt1621 is a therapy that targets the underlying pathophysiology of tk2d by restoring mitochondrial dna (mtdna) replication fidelity. mt1621 consists of a combination of deoxynucleosides (the building blocks of mtdna) given orally. deoxynucleoside combination therapy improves nucleotide balance, increases mtdna copy number, improves cell function, and prolongs life in preclinical models of tk2d. this is a phase 3b, prospective, single-arm, multicenter, open-label treatment study to assess the efficacy and safety of mt1621 in treatment naïve pediatric and adolescent subjects \<18 years of age with tk2d. the study seeks to enroll approximately 16 subjects globally in this ultra rare disease.

Eligibility criteria:
inclusion criteria: * subject must be aged birth to \<18 years of age on the day of consent. * diagnosis of tk2 deficiency based on confirmed disease-causing mutation(s) in the tk2 gene. * onset of tk2d at ≤12 years of age as defined as the age at which the first tk2d symptom occurred. exclusion criteria: * documented clinically significant central nervous system involvement. * alt or ast \>3 x upper limit of normal and total bilirubin \> 2 x uln or international normalized ratio (inr) \>1.5. * etco2\>45 mmhg if not on ventilatory support * current or prior treatment with nucleos(t)ides for tk2d.

Keywords: tk2 tk2d mitochondrial disorder mitochondrial disease mitochondria deoxythymidine/deoxythymidine substrate enhancement therapy dc/dt deoxythymidine/deoxythymidine primary mitochondrial myopathy mitochondrial depletion syndrome muscle weakness muscle atrophy loss of mobility thymidine kinase 2 deficiency
prevalence and burden of bronchiectasis in tuberculous patients

Conditions: Pulmonary Tuberculoses

Summary: bronchiectasis was described in the early 19th century by laennec. bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree

bronchiectasis was described in the early 19th century by laennec. bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree. the prevalence of bronchiectasis is age-related and occurs in every age group and in the pre-antibiotic era . it most often began in childhood. recent evidence shows that bronchiectasis disproportionately affects women and older individuals and will be contributing to increase in healthcare burden.\[3\] international data show an increase in the prevalence of bronchiectasis over recent years.

Eligibility criteria:
inclusion criteria: * 1-patients were diagnosed to have tuberculosis by sputum culture and gene x pert. 2-patients were diagnosed to have bronchiectasis after lab and radiological examination as well as clinical score. 3- patients diagnosed as bronchiectasis after history of tuberculosis or anti tuberculosis treatment with positive or negative tuberculous culture in the time of research. exclusion criteria: * 1-patients presented with other pulmonary diseases. 2-chronic liver and renal disease . 3- lung cancer and tumors. 4- patients were previously diagnosed as bronchiectasis .
smet12 and toripalimab combined chemotherapy in patients with egfr positive advanced non-small cell lung cancer (nsclc)

Conditions: EGFR Positive Non-small Cell Lung Cancer

Summary: this is a single-arm, sequential study assessing the efficacy and safety of smet12 and toripalimab combined chemotherapy in patients with egfr positive advanced non-small cell lung cancer (nsclc) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.the primary objective is to evaluate the anti-tumor activity and safety of smet12 and toripalimab combined chemotherapy in patients with egfr positive advanced nsclc.


Eligibility criteria:
inclusion criteria: * 1. has fully understood and voluntarily signed an informed consent form for this study , willing and able to comply with study procedures. 2. age ≥ 18 years. 3. histologically confirmed egfr positive (immunohistochemistry ≥ \[+\]) advanced nsclc ,including: (1) cohort a: treatment-naïve subjects; (2) cohort b: subjects resistant to first-line treatment contain immune checkpoint inhibitors (stability period \> 3 months). 4. at least one measurable lesion via recist v1.1 criteria 5. eastern cooperative oncology group (ecog) performance status 0 or 1. 6. expected survival ≥ 3 months. 7. adequate organ function . exclusion criteria: * 1. driver gene-positive (egfr, alk, ros1) . 2. history of dual primary malignancies within the past 5 years. 3. active autoimmune diseases or a history of autoimmune disorders requiring systemic corticosteroid therapy. 4. systemic infections requiring systemic treatment. 5. known central nervous system metastases or other central nervous system diseases or abnormalities deemed unsuitable for inclusion in this study by the investigator. 6. fertile individuals unable to maintain effective contraception during the trial. 7. subjects in cohort b who have received prior docetaxel treatment. 8. subjects in cohort b who experienced grade 3 or higher immune-related adverse events during first-line treatment with immune checkpoint inhibitors. 9. individuals deemed unsuitable for participation in this clinical trial by the investigator for various reasons .
treatment of steroid-refractory acute graft-versus-host disease with mesenchymal stromal cells versus best available therapy

Conditions: Steroid-refractory Acute Graft-versus-host Disease

Summary: the primary purpose of this trial is to demonstrate the superiority of mc0518 compared to the first used best available therapy (bat) with respect to overall response rate (orr) at day 28 and/or overall survival (os) until visit month 24 in adult and adolescent subjects with steroid-refractory acute graft-versus-host disease (sr-agvhd).


Eligibility criteria:
inclusion criteria: * participant had a previous allogeneic hsct as indicated for non-malignant (including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies, and bone marrow failure syndromes) or haematological malignant disease, irrespective of human leukocyte antigen match * participant has been clinically diagnosed with grade ii to iv agvhd at the screening visit * participant has experienced failure of previous first-line agvhd treatment (ie, sr-agvhd), defined as: a) agvhd progression within 3 to 5 days of therapy onset with \>= 2 mg/kg/day of prednisone equivalent or b) failure to improve within 5 to 7 days of treatment initiation with \>= 2 mg/kg/day of prednisone equivalent or c) incomplete response after \> 28 days of immunosuppressive treatment including at least 5 days with \>= 2 mg/kg/day of prednisone equivalent * participant has an estimated life expectancy \> 28 days at the screening visit * male or female participant who is \>= 12 years of age at the screening visit exclusion criteria: * participant has overt relapse or progression or persistence of the underlying disease at the screening visit * participant has received the last hsct for a solid tumour disease * participant has gvhd overlap syndrome at the screening visit * participant has received systemic first line treatment for agvhd other than steroids and a prophylaxis with other than calcineurin inhibitors, mammalian target of rapamycin (mtor) inhibitors, anti-thymocyte globulin (atg), mycophenolate mofetil (mmf), methotrexate (mtx), and / or cyclophosphamide before the screening visit * participant has a known pregnancy (as confirmed by a positive pregnancy test at the screening visit) and or is breastfeeding at the screening visit * participant has received treatment with any other investigational agent within 30 days or 5 half-lives (whichever is longer) before the screening visit (compliance to be confirmed for the period between the screening visit and the baseline visit at the baseline visit).
antibiotic resistant bacteria among patients with severe intraabdominal infections

Conditions: Complicated Intra-Abdominal Infections

Summary: the objectives of the study were: 1. to study risk factors for colonization and infection with antibiotic resistant bacteria among patients with severe iai before and after antibiotic treatment and surgical intervention. 2. to study species changes in the rectal flora among patients with severe iai before and after antibiotic treatment and surgical intervention. 3. to review guidelines for antibiotic use in participating units. 4. to evaluate surgical antibiotic prophylaxis and treatment in relation to risk for colonization and infection with antibiotic resistant bacteria among patients with severe iai 5. to use the results from the study in the process of a more appropriate use of antibiotics in participating units and care of patients with severe iai. 6. to study the dynamics of extended-spectrum beta-lactamase producing and wild-type enterobacteriaceae in patients with suspected severe intra abdominal infections before, during and after antibiotic treatment.

in order to evaluate if standard empirical treatment was adequate in relation to resistance pattern among most prevalent species at admission we need another 70 patients to be included with at least data and cultures from admission.

Eligibility criteria:
inclusion criteria: * patients with evidence of intra-abdominal infections that require surgical intervention will be eligible. * in addition will patients with intra-abdominal abscess confirmed with ct/ultrasound be eligible, but not treated with surgical intervention if estimated to require at least 5 days antibiotic treatment, with a severity needing initial intravenous administration of antibiotics. exclusion criteria: * age under 18 years

Keywords: antibiotic resistance antibiotic treatment